These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 834952)

  • 21. A preliminary investigation of the association between serum uric acid and impaired renal function.
    Chen YC; Su CT; Wang ST; Lee HD; Lin SY
    Chang Gung Med J; 2009; 32(1):66-71. PubMed ID: 19292941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for the existence of circulating monoclonal B-lymphocytes in multiple myeloma patients.
    Cassel A; Leibovitz N; Hornstein L; Quitt M; Aghai E
    Exp Hematol; 1990 Dec; 18(11):1171-3. PubMed ID: 2226677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Non-excretory plasma cell myeloma (apropos of 2 new cases)].
    Menkes CJ; Herreman G; Preud'homme JL; Godeau P; Delbarre F
    Nouv Presse Med; 1972 Jan; 1(5):309-12. PubMed ID: 4551593
    [No Abstract]   [Full Text] [Related]  

  • 24. J-shaped mortality relationship for uric acid in CKD.
    Suliman ME; Johnson RJ; García-López E; Qureshi AR; Molinaei H; Carrero JJ; Heimbürger O; Bárány P; Axelsson J; Lindholm B; Stenvinkel P
    Am J Kidney Dis; 2006 Nov; 48(5):761-71. PubMed ID: 17059995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prognostic factors in multiple myeloma].
    Pick AI; Tamir R; Vana D; Duczyminer-Kahana M; Weiss H; Lurie H; Dawidowich J; Meyerson E; Gelernter I
    Harefuah; 1990 Apr; 118(8):437-42. PubMed ID: 2358224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapeutic application of sequential bone marrow biopsy in myeloma: analysis of 13 medullary biopsies].
    Paule B; Médicis P; Clerc D; Bennet P; Bisson M; Massias P
    Biomed Pharmacother; 1986; 40(7):261-4. PubMed ID: 3814757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
    Urbańska-Ryś H; Robak T
    Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hereditary nephropathy associated with hyperuricemia and gout.
    Puig JG; Miranda ME; Mateos FA; Picazo ML; Jiménez ML; Calvin TS; Gil AA
    Arch Intern Med; 1993 Feb; 153(3):357-65. PubMed ID: 8427538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Study of hyperuricemia in Tahiti. 31 cases hospitalized at the Territorial Hospital Center in Papeete (Tahiti)].
    Prigent D; Spiegel A; Brodin S; Gras C
    Med Trop (Mars); 1992; 52(1):63-6. PubMed ID: 1602955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies.
    Mittelman M; Zeidman A; Kanter P; Katz O; Oster H; Rund D; Neumann D
    Eur J Haematol; 2004 Mar; 72(3):155-65. PubMed ID: 14962233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The role of homeostatic function of the kidneys in the development of hyperuricemia].
    Karvé MD; Shamarin VM; Vinogradova IV; Kiseleva NS; Ankhimiuk ON
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1989; (12):54-9. PubMed ID: 2624846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.
    Caligaris-Cappio F; Bergui L; Tesio L; Pizzolo G; Malavasi F; Chilosi M; Campana D; van Camp B; Janossy G
    J Clin Invest; 1985 Sep; 76(3):1243-51. PubMed ID: 2931452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency of hyperuricemia and effect of calcineurin inhibitors on serum uric acid levels in liver transplanted children.
    Tumgor G; Arikan C; Kilic M; Aydogdu S
    Pediatr Transplant; 2006 Sep; 10(6):665-8. PubMed ID: 16911488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease.
    Hungria VT; Latrilha MC; Rodrigues DG; Bydlowski SP; Chiattone CS; Maranhão RC
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):51-60. PubMed ID: 14574458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cytogenetical and clinico-hematological changes in myeloma disease].
    Dubrova SE; Dygin VP; Ushakova EA
    Tsitologiia; 1966; 8(2):241-9. PubMed ID: 5984072
    [No Abstract]   [Full Text] [Related]  

  • 36. Reversible renal insufficiency in multiple myeloma.
    Bernstein SP; Humes HD
    Arch Intern Med; 1982 Nov; 142(12):2083-6. PubMed ID: 7138157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple-myeloma: review of 231 cases.
    Advani SH; Soman CS; Talwalkar GV; Lyer YS; Bhatia HM
    Indian J Cancer; 1978 Jun; 15(2):55-61. PubMed ID: 374240
    [No Abstract]   [Full Text] [Related]  

  • 38. Bone marrow histology in multiple myeloma: autopsy studies on treated and untreated patients.
    Hashimoto N
    Nihon Ketsueki Gakkai Zasshi; 1986 Dec; 49(8):1774-83. PubMed ID: 3564858
    [No Abstract]   [Full Text] [Related]  

  • 39. [Physical and mental fatigue of probable hyperuricemia origin].
    Karamians SJ
    Acta Med Iran; 1975; 18(1-2):61-8. PubMed ID: 7923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of plasma cell myeloma.
    Bergsagel DE
    Annu Rev Med; 1979; 30():431-43. PubMed ID: 162450
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.